Francisco Leon work email
- Valid
- Valid
- Valid
- Valid
Francisco Leon personal email
An immunologist by training, my career is highlighted by several successful entrepreneurial pursuits, including Provention Bio, which I co-founded and served as Chief Scientific Officer (acquired by Sanofi in 2023) and Celimmune, which I co-founded and served as CEO and Chief Medical Officer (acquired by Amgen in 2017). My scientific and corporate mission is the development of interventions to restore immune balance, intercepting or preventing immune-mediated diseases. Experienced in the main areas of immunology: Immunodeficiencies, allergy, infectious diseases, immuno-oncology, transplantation and, in particular, autoimmunity and vaccines. I have led R&D projects and teams in diverse settings from start-ups to Big Pharma and am fluent in all phases of drug development and commercialization. I have expertise in the design and execution of strategies and trials for rapid and cost-effective de-risking of experimental medicines and solutions ("rapid go/no-go"). I have authored or co-authored over 100 peer-reviewed articles, book chapters and patents. And I have led or participated in the development of several approved products: Provention's teplizumab/TZIELD®, AZ’s benralizumab/FASENRA®; BMS's abatacept/ORENCIA®, belatacept/NULOJIX®; and Janssen’s ustekinumab/STELARA® and guselkumab/TREMFYA®.Overall, I am passionate about translational research, innovation and disruptive ideas which may help people in need.
Tolerance Bio
View- Website:
- tolerancebio.com
- Employees:
- 17
-
Founder, Ceo, ChairmanTolerance BioWashington, Dc, Us
-
Founder, CeoTolerance Bio Jan 2024 - PresentFounder and CEO of Tolerance Bio, a biotech start-up focused on improving healthspan by restoring and preserving the function of the thymus, a key regulator of immune tolerance. https://www.tolerancebio.com/
-
Co-FounderPaulex Bio Jan 2024 - PresentCo-founder of Paulex Bio, a clinical-stage biotech company working towards a world without diabetes. Paulex is developing preventative and regenerative therapies for Type-1 and Type-2 Diabetes. https://paulexbio.com/ -
Co-FounderAvalor Therapeutics Jan 2024 - PresentCo-Founder of Avalor Therapeutics, a biotech start-up developing breakthrough precision medicine for chronic inflammation. Avalor is initially focused on disease modification in osteoarthritis. https://avalortx.com/ -
Co-FounderPraetorian Bio Jan 2024 - PresentPraetorian Bio is a biotech startup in stealth mode, developing a revolutionary preventative approach for oral health. -
Board MemberLapix Therapeutics Jan 2024 - PresentBoston, Massachusetts, UsBoard Director at Lapix Therapeutics, clinical-stage biopharma company developing novel, orally bioavailable immune system restoration therapies for autoimmune diseases and oncology. https://lapix.com/ -
Founding Partner, Board DirectorVaxdyn Sl Jan 2020 - PresentVaxdyn is a biotechnology company located in Seville, Spain, developing a vaccine platform for antibiotic-resistant bacteria, such as Klebsiella, Acinetobacter and Pseudomonas. Our goal is to decrease the impact on public health of infections caused by drug-resistant pathogens. https://vaxdyn.com/ -
Co-Founder, PartnerGluten Detect (Glutenostics Llc) Jun 2016 - PresentIndianapolis, In, UsGlutenostics commercializes rapid detection assays (GlutenDetect Stool and Gluten Detect Urine) and lab-based assays (iVYCHECK lateral flow test, iVYDAL ELISA) to help people avoiding gluten to be more compliant with their diets. https://glutendetect.us/ -
Founder, PresidentPharmimmune Jul 2010 - PresentCompany ideation and consultancy firm.
-
Chief Scientific Officer, Provention Bio - A Sanofi CompanySanofi Apr 2023 - Jan 2024Paris, France, FrAfter the acquisition, I help transition and advance the Provention Bio pipeline in Sanofi, focusing on Tzield (PROTECT completion and regulatory activities, intellectual property development, life cycle). -
Co-Founder, Chief Scientific OfficerProvention Bio (Acquired By Sanofi In 2023) Oct 2016 - Apr 2023Co-Founder, Chief Scientific Officer, former Board Director (2018-2019), former Chairman of the Scientific Advisory Board (2017). Provention Bio was acquired by Sanofi in April 2023.Provention was a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics and cutting edge solutions to intercept and prevent immune-mediated disease. Our founding mission was to reduce the high-morbidity/mortality and escalating costs of autoimmune and inflammatory diseases, such as type 1 diabetes, celiac disease, Crohn’s disease, ulcerative colitis, lupus and emerging viruses. Our pioneering approach was to “predict” and “pre-empt” immune-mediated disease – to identify at-risk patients and intervene before the targeted disease begins, re-appears or progresses.At Provention, I had the privilege of leading scientific aspects of our programs, with focus on the advancement of teplizumab/TZIELD®, and responsibility for our celiac (PRV-015, anti-IL-15), lupus/gene therapy (PRV-3279, CD32B/CD79B bi-specific) and coxsackie vaccine (PRV-101) programs. I functionally managed Translational Medicine, Biomarkers, Intellectual Property and Pharmacokinetic teams, and supported Business Development, Investor Relations, Corporate Communications and Commercial.
-
Adjunct Research Associate Professor Of MedicineJefferson Medical College, Dept. Of Gastroenterology Jun 2011 - Dec 2020UsProvided advice on innovative clinical trials in celiac disease. -
Co-Founder, Ceo, Chief Medical OfficerCelimmune (Acquired By Amgen In 2017) Feb 2015 - Oct 2018Co-founded Celimmune, an immunotherapy company focused on gastrointestinal autoimmunity. CEO and Chief Medical Officer from Feb 2015 to November 2017, when Amgen acquired Celimmune following completion of Phase 2 clinical trials of AMG 714 (anti-IL-15 mAb) in celiac and refractory celiac disease Type II (pre-EATL/intestinal T cell lymphoma).
-
Vice President & Head, Immunology Translational MedicineJanssen/J&J Sep 2010 - Jan 2015Raritan, New Jersey, UsFounded the Immunology Translational Medicine team at Centocor, later Janssen. Responsible for translational strategies and early clinical development of biologic and small molecule therapies for immune-mediated diseases (Phase 0 to proof-of-concept) at Johnson & Johnson. -
Vice President & Chief Medical OfficerAlba Therapeutics Sep 2007 - Sep 2010UsHead of Clinical Development. Early and Late Development including Regulatory. Celiac Disease, Crohn's Disease. Led clinical aspects of the out-licensing of larazotide acetate to Cephalon/TEVA. -
Director, Clinical Development, Inflammation & RespiratoryMedimmune/Az Sep 2006 - Sep 2007Gaithersburg, Maryland, UsInflammation therapeutic area, focus in Asthma, serving as development leader for the anti-IL-9 and anti-IL5R programs (clinical lead for Phase 1 FIH study for benralizumab, FASENRA) as well as earlier stage programs. Contributed to biomarker efforts in mucosal vaccines (FluMist), life-cycle management and corporate and business development activities. -
Director, Clinical Discovery, Immunology & OncologyBristol-Myers Squibb Sep 2004 - Aug 2006Lawrence Township, Nj, UsEarly development of immune modulators in Immunology and Oncology. Phase I-IIa, biomarkers, POC, clinical pharmacology. Focus on costimulation (abatacept/ORENCIA sBLA, belatacept/NULOJIX biomarker patents, immune monitoring of ipilimumab/YERVOY responses, in-licensing discussions for nivolumab/OPDIVO with Ono) and chemokine receptors (development team co-leader for a small molecule inhibitor of CCR2). -
Research Fellow, Lab. Of Clinical Investigation, Lab. Of Molecular Immunology, NiaidNational Institutes Of Health (Nih) Jan 2002 - Aug 2004Bethesda, Md, UsPostdoctoral Research Fellow at the Laboratory of Clinical Investigation (Head: Dr. Warren Strober), reorganized in 2004 as Laboratory of Molecular Immunology (Head: Dr. Phil Murphy), at the National Institutes of Allergy and Infectious Diseases, National Institutes of Health (LCI-LMI/NIAID/NIH), Bethesda, MD, Feb 2002- Sept 2004. Study of the role of dendritic cells (DC) in the pathogenesis of Inflammatory Bowel Disease (IBD), psoriasis and other autoimmune diseases, under the supervision of Dr. Brian Kelsall, Head of the Immunobiology Section. Development of novel immuno-modulatory therapeutics, pre-clinical validation, immunological monitoring of phase I and IIa clinical trials.
Francisco Leon Skills
Francisco Leon Education Details
-
Universidad Autónoma De MadridMucosal Immunology -
Hospital Ramon Y Cajal, MadridClinical Immunology
-
Universidad Autónoma De MadridAllergy And Immunology Residency Program
Frequently Asked Questions about Francisco Leon
What company does Francisco Leon work for?
Francisco Leon works for Tolerance Bio
What is Francisco Leon's role at the current company?
Francisco Leon's current role is Founder, CEO, Chairman.
What is Francisco Leon's email address?
Francisco Leon's email address is fl****@****bio.com
What schools did Francisco Leon attend?
Francisco Leon attended Universidad Autónoma De Madrid, Hospital Ramon Y Cajal, Madrid, Universidad Autónoma De Madrid.
What are some of Francisco Leon's interests?
Francisco Leon has interest in Children.
What skills is Francisco Leon known for?
Francisco Leon has skills like Immunology, Clinical Development, Clinical Trials, Drug Development, Oncology, Vaccines, Infectious Diseases, Drug Discovery, Molecular Biology, Life Sciences, Biochemistry, Biologics.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial